Inside informationEnglish
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 30/06/2026, 07:00
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 110274_20260630